OverviewChartNewsTraderScreen

Vaxart/  US92243A2006  /

IEX
2024-10-23  9:59:50 PM Chg. 0.00 Volume Bid- Ask- High Low
0.78USD -0.33% 6,911
Turnover: 5,378.03		 -Bid Size: - -Ask Size: - 0.79 0.77
GlobeNewswire 08-30 Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 08-28 Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal...
GlobeNewswire 08-08 Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results
GlobeNewswire 08-02 Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8
GlobeNewswire 06-17 Vaxart Provides Business Update
GlobeNewswire 06-14 Vaxart Announces $40 Million Underwritten Offering of Common Stock
GlobeNewswire 06-13 Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b S...
GlobeNewswire 05-23 Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 05-13 Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire 05-07 Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13
GlobeNewswire 04-30 Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
GlobeNewswire 03-27 Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
GlobeNewswire 03-20 Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 03-14 Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
GlobeNewswire 03-07 Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
GlobeNewswire 03-06 Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
GlobeNewswire 02-05 Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Nex...
GlobeNewswire 01-19 Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Eva...
GlobeNewswire 01-16 Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
GlobeNewswire 01-16 Vaxart, Inc. Announces Management Change
GlobeNewswire 2023-12-21 Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating...
GlobeNewswire 2023-11-02 Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
GlobeNewswire 2023-11-02 Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
GlobeNewswire 2023-10-26 Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November ...
GlobeNewswire 2023-10-11 Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19